– USA, CA – Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of Dr. Elizabeth Yeu (M.D.) to its Board of Directors while continuing to serve as the Chief Medical Advisor in bringing proven clinical leadership to the Board.
She will also join the Science and Technology Committee.
“We are delighted to have Dr. Yeu join our Board of Directors during a pivotal time for the company as we approach the potential commercialization of TP-03, our lead investigational product for the treatment of Demodex blepharitis. Dr. Yeu is a prominent and well-respected thought leader and clinician and has a deep understanding of the unmet needs in eye care. I am grateful for her expertise and guidance as we plan for the company’s growth and pipeline expansion,” said CEO, Dr. Bobak Azamian.
About Dr. Elizabeth Yeu
Dr. Yeu brings a wealth of eye care experience to the Tarsus Board, having authored hundreds of articles and conducted numerous lectures on subjects such as refractive cataract surgery, anterior segment reconstruction, and external ocular disease management. In addition to serving as Tarsus’ Chief Medical Advisor since August 2020, Dr. Yeu is a partner and practicing ophthalmologist at Virginia Eye Consultants and Medical Director at Virginia Surgery Center. She also provides guidance and governance across several national medical boards and committees, including as an examiner for the American Board of Ophthalmology and as the Chair of the Cataract Section of Ophthalmic News & Education (ONE) Network for the American Academy of Ophthalmology. Dr. Yeu is also an Executive Committee member and the current Secretary for the American Society of Cataract and Refractive Surgery and, in 2023, she will become the ASCRS President.
“Tarsus has made remarkable progress in advancing TP-03 for the treatment of Demodex blepharitis, and I am honored to have the opportunity to broaden my responsibility by joining the Board of Directors and the Science and Technology Committee,” said Dr. Yeu. “The company is at the forefront of developing multiple innovative therapeutics that have the potential to make a meaningful difference in many patients’ daily lives, and I am delighted to contribute towards the strategic path of the company.”
Dr. Yeu currently serves on the Boards of Directors of STAAR Surgical, Ocular Science, and the Virginia Eye Foundation. She also serves as an Executive Committee Member of CVP Physicians, Mid Atlantic. Dr. Yeu earned her M.D. through an accelerated and combined undergraduate/medical school program at the University of Florida College of Medicine. She completed her ophthalmology residency at Rush University Medical Center in Chicago, where she served as Chief Resident. She then completed a fellowship in cornea, anterior segment, and refractive surgery at the Cullen Eye Institute, Baylor College of Medicine, where she also served as an Assistant Professor. She continues to train residents as an Assistant Professor at the Eastern Virginia Medical School.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet needs across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. In addition, Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in Phase 1 clinical trial.
For more information: https://tarsusrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.